Three types of striational antibodies in myasthenia gravis

Shigeaki Suzuki, Kimiaki Utsugisawa, Yuriko Nagane, Norihiro Suzuki

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Myasthenia gravis (MG) is caused by antibodies that react mainly with the acetylcholine receptor on the postsynaptic site of the neuromuscular junction. A wide range of clinical presentations and associated features allow MG to be classified into subtypes based on autoantibody status. Striational antibodies, which react with epitopes on the muscle proteins titin, ryanodine receptor (RyR), and Kv1.4, are frequently found in MG patients with late-onset and thymoma. Antititin and anti-RyR antibodies are determined by enzyme-linked immunosorbent assay or immunoblot. More recently, a method for the detection of anti-Kv1.4 autoantibodies has become available, involving 12-15% of all MG patients. The presence of striational antibodies is associated with more severe disease in all MG subgroups. Anti-Kv1.4 antibody is a useful marker for the potential development of lethal autoimmune myocarditis and response to calcineurin inhibitors. Detection of striational antibodies provides more specific and useful clinical information in MG patients.

Original languageEnglish
Article number740583
JournalAutoimmune Diseases
Volume1
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

Myasthenia Gravis
Antibodies
Ryanodine Receptor Calcium Release Channel
Autoantibodies
Connectin
Thymoma
Muscle Proteins
Neuromuscular Junction
Myocarditis
Cholinergic Receptors
Autoimmunity
Epitopes
Anti-Idiotypic Antibodies
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology and Microbiology (miscellaneous)
  • Immunology

Cite this

Three types of striational antibodies in myasthenia gravis. / Suzuki, Shigeaki; Utsugisawa, Kimiaki; Nagane, Yuriko; Suzuki, Norihiro.

In: Autoimmune Diseases, Vol. 1, No. 1, 740583, 2011.

Research output: Contribution to journalArticle

Suzuki, Shigeaki ; Utsugisawa, Kimiaki ; Nagane, Yuriko ; Suzuki, Norihiro. / Three types of striational antibodies in myasthenia gravis. In: Autoimmune Diseases. 2011 ; Vol. 1, No. 1.
@article{eaf19269da5b4030bef69c0935213920,
title = "Three types of striational antibodies in myasthenia gravis",
abstract = "Myasthenia gravis (MG) is caused by antibodies that react mainly with the acetylcholine receptor on the postsynaptic site of the neuromuscular junction. A wide range of clinical presentations and associated features allow MG to be classified into subtypes based on autoantibody status. Striational antibodies, which react with epitopes on the muscle proteins titin, ryanodine receptor (RyR), and Kv1.4, are frequently found in MG patients with late-onset and thymoma. Antititin and anti-RyR antibodies are determined by enzyme-linked immunosorbent assay or immunoblot. More recently, a method for the detection of anti-Kv1.4 autoantibodies has become available, involving 12-15{\%} of all MG patients. The presence of striational antibodies is associated with more severe disease in all MG subgroups. Anti-Kv1.4 antibody is a useful marker for the potential development of lethal autoimmune myocarditis and response to calcineurin inhibitors. Detection of striational antibodies provides more specific and useful clinical information in MG patients.",
author = "Shigeaki Suzuki and Kimiaki Utsugisawa and Yuriko Nagane and Norihiro Suzuki",
year = "2011",
doi = "10.4061/2011/740583",
language = "English",
volume = "1",
journal = "Autoimmune Diseases",
issn = "2090-0422",
publisher = "Hindawi Publishing Corporation",
number = "1",

}

TY - JOUR

T1 - Three types of striational antibodies in myasthenia gravis

AU - Suzuki, Shigeaki

AU - Utsugisawa, Kimiaki

AU - Nagane, Yuriko

AU - Suzuki, Norihiro

PY - 2011

Y1 - 2011

N2 - Myasthenia gravis (MG) is caused by antibodies that react mainly with the acetylcholine receptor on the postsynaptic site of the neuromuscular junction. A wide range of clinical presentations and associated features allow MG to be classified into subtypes based on autoantibody status. Striational antibodies, which react with epitopes on the muscle proteins titin, ryanodine receptor (RyR), and Kv1.4, are frequently found in MG patients with late-onset and thymoma. Antititin and anti-RyR antibodies are determined by enzyme-linked immunosorbent assay or immunoblot. More recently, a method for the detection of anti-Kv1.4 autoantibodies has become available, involving 12-15% of all MG patients. The presence of striational antibodies is associated with more severe disease in all MG subgroups. Anti-Kv1.4 antibody is a useful marker for the potential development of lethal autoimmune myocarditis and response to calcineurin inhibitors. Detection of striational antibodies provides more specific and useful clinical information in MG patients.

AB - Myasthenia gravis (MG) is caused by antibodies that react mainly with the acetylcholine receptor on the postsynaptic site of the neuromuscular junction. A wide range of clinical presentations and associated features allow MG to be classified into subtypes based on autoantibody status. Striational antibodies, which react with epitopes on the muscle proteins titin, ryanodine receptor (RyR), and Kv1.4, are frequently found in MG patients with late-onset and thymoma. Antititin and anti-RyR antibodies are determined by enzyme-linked immunosorbent assay or immunoblot. More recently, a method for the detection of anti-Kv1.4 autoantibodies has become available, involving 12-15% of all MG patients. The presence of striational antibodies is associated with more severe disease in all MG subgroups. Anti-Kv1.4 antibody is a useful marker for the potential development of lethal autoimmune myocarditis and response to calcineurin inhibitors. Detection of striational antibodies provides more specific and useful clinical information in MG patients.

UR - http://www.scopus.com/inward/record.url?scp=84861460473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861460473&partnerID=8YFLogxK

U2 - 10.4061/2011/740583

DO - 10.4061/2011/740583

M3 - Article

VL - 1

JO - Autoimmune Diseases

JF - Autoimmune Diseases

SN - 2090-0422

IS - 1

M1 - 740583

ER -